Pharmaniaga is committed to providing affordable and high quality medicines as well as services to patients thereby allowing them to have better access to healthcare that enhances lives. Our partnership with one of the largest international manufacturers of pharmaceutical products and Drugs for Neglected Diseases Initiative (DNDi), a Swiss-based non-profit drug research and development organisation has allowed us to expand our product range to include Hepatitis C treatment regimes. More importantly, with this latest achievement we are able to provide affordable treatment options to patients in Malaysia. There are an estimated 500,000 patients in the country infected with Hepatitis C and about 2,000 new cases are reported every year. Hepatitis C has become a major public health concern in Malaysia. Thus, it is crucial to increase access to its treatment. The key objective of the collaboration between the three parties is to make the treatment accessible and affordable.
We are pleased to inform that the Group has made significant strides in our product pipeline for the therapeutic segments of oncology as well as vaccine. We have engaged a regional partner to collaborate in the trading and technology transfer of selected oncology and vaccine products. In addition, we are also playing a role in the fight against rising levels of diabetes in Malaysia. Following through from our launch of SweetRoyale Natural Stevia, a natural sweetener, we released new variants for the consumer market including SweetRoyale Brown Stevia as well as SweetRoyale White Stevia.